No association between major depression with and without childhood adversity and the stress hormone copeptin

Michael Kaczmarczyk, Carsten Spitzer, Katja Wingenfeld, Klaus Wiedemann, Linn K. Kuehl, Katharina Schultebraucks, Christian Eric Deuter & Christian Otte

To cite this article: Michael Kaczmarczyk, Carsten Spitzer, Katja Wingenfeld, Klaus Wiedemann, Linn K. Kuehl, Katharina Schultebraucks, Christian Eric Deuter & Christian Otte (2020) No association between major depression with and without childhood adversity and the stress hormone copeptin, European Journal of Psychotraumatology, 11:1, 1837511, DOI: 10.1080/20008198.2020.1837511

To link to this article: https://doi.org/10.1080/20008198.2020.1837511
No association between major depression with and without childhood adversity and the stress hormone copeptin

Michael Kaczmarczyk a, Carsten Spitzer a, Katja Wingenfeld a, Klaus Wiedemann b, Linn K. Kuehl a, Katharina Schultebrakcs d, Christian Eric Deuter a and Christian Otte a

aDepartment of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité, Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; bDepartment of Psychosomatic Medicine, University Medicine Rostock, Rostock, Germany; cDepartment of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; dVagelos School of Physicians and Surgeons, Department of Emergency Medicine, Columbia University Irving Medical Center, New York, NY, USA

ABSTRACT
Background: Adverse childhood experiences (ACE) are associated with an increased risk of major depressive disorder (MDD) and hypothalamic-pituitary-adrenal (HPA) axis dysregulation. Within the HPA axis, corticotropin-releasing hormone and vasopressin (AVP) synergistically stimulate the release of adrenocorticotropic hormone, which promotes cortisol release. The cleavage product copeptin is produced during AVP synthesis and is a surrogate marker of AVP release. Children with ACE and young adults with depressive symptoms have higher levels of copeptin than healthy controls.

Objective: To uncover the effects of MDD and ACE on copeptin levels in adult females.

Methods: We recruited 94 women (mean age: 34.0 ± 3.6 years): 23 with MDD and ACE, 24 with MDD without ACE, 22 with ACE without MDD, and 25 healthy controls. ACE was defined as repeated sexual or physical abuse at least once a month over at least one year before the age of 18 years. MDD was defined by the DSM-IV criteria. Copeptin plasma levels were measured with an immunoluminometric assay.

Results: The four groups did not differ in demographic variables. We found a significant negative correlation between body mass index (BMI) and copeptin plasma levels ($r = -0.21; p = 0.045$). Copeptin plasma levels did not differ between the four groups after controlling for BMI.

Conclusion: Neither MDD nor ACE was associated with altered plasma copeptin levels. Thus, copeptin does not seem to play a major role in MDD and ACE in adult females.

No hay asociación entre la depresión mayor con y sin adversidad infantil y la hormona del estrés copeptina

Antecedentes: Las experiencias adversas de la infancia (EAI) se asocian con un mayor riesgo de trastorno depresivo mayor (TDM) y desregulación del eje hipotálamo-hipohipofisario-adenal (HPA). Dentro del eje HPA, la hormona liberadora de corticotropina y la vasopresina (AVP) estimulan sinérgicamente la liberación de la hormona adrenocorticotrópica, que promueve la liberación de cortisol. El producto de escisión copeptina se produce durante la síntesis de AVP y es un marcador sustituto de la liberación de AVP. Los niños con EAI y los adultos jóvenes con síntomas depresivos tienen niveles más altos de copeptina que los controles sanos.

Objetivo: Descubrir los efectos del TDM y la EAI en los niveles de copeptina en mujeres adultas.

Métodos: Se reclutaron 94 mujeres (edad media: 34.0 ± 3.6 años): 23 con TDM y EAI, 24 con TDM sin EAI, 22 con EAI sin TDM y 25 controles sanos. La EAI se definió como abuso sexual o físico repetido al menos una vez al mes durante al menos un año antes de los 18 años. El TDM fue definido por los criterios del DSM-IV. Los niveles plasmáticos de copeptina se midieron con un ensayo inmunoluminométrico.

Resultados: Los cuatro grupos no difirieron en las variables demográficas. Encontramos una correlación negativa significativa entre el índice de masa corporal (IMC) y los niveles plasmáticos de copeptina ($r = -0.21; p = 0.045$). Los niveles plasmáticos de copeptina no difirieron entre los cuatro grupos después de controlar el IMC.

Conclusión: Ni el TDM ni la EAI se asociaron con niveles alterados de copeptina plasmática. Por tanto, la copeptina no parece desempeñar un papel importante en el TDM y la EAI en mujeres adultas.

有无童年期不良经历的重性抑郁与应激激素肽素之间无关联

背景: 童年期不良经历 (ACE) 与重性抑郁症 (MDD) 和下丘脑-垂体-肾上腺 (HPA) 轴失调的风险增加有关。在HPA轴内，促肾上腺皮质释放激素和加压素 (AVP) 协同刺激促肾上
1. Introduction

Activation of the hypothalamic-pituitary-adrenal (HPA) axis by physiological or psychosocial stressors stimulates the release of corticotropin-releasing hormone (CRH) from the hypothalamus, which in turn stimulates adrenocorticotropic hormone (ACTH) production, thus promoting cortisol secretion. The hypothalamic hormone vasopressin (AVP), synergistically with CRH, stimulates the secretion of ACTH and cortisol (Katan & Christ-Crain, 2010). Measuring CRH and AVP levels to monitor stress-mediated activation of the HPA axis is challenging because they are released in a pulsatile pattern, are biochemically unstable, and are rapidly degraded and cleared from plasma within minutes. The 39 amino acids glycopeptide copeptin, a cleavage product of AVP synthesis, is more stable at room temperature and easier to measure in plasma (Katan & Christ-Crain, 2010; Morgenthaler, Struck, Alonso, & Bergmann, 2006; Spanakakis, Wand, Ji, & Golden, 2016). Copeptin levels are elevated in many severe medical conditions, including acute myocardial infarction and stroke (Katan & Christ-Crain, 2010; Lewandowski & Brabant, 2016), an effect attributable to increased AVP levels in response to stress.

Research on the link between psychosocial stress and copeptin is just emerging. Median copeptin and median cortisol levels were increased in a group of healthy subjects immediately after the Trier Social Stress Test (TSST) (mean age: 22.5 years) (Siegenthaler, Walti, Urwyler, Schuetz, & Christ-Crain, 2014). Spanakakis et al. (2016) reported higher baseline copeptin levels in men compared with women. After the TSST, the authors found a positive association between the percent change in copeptin levels and cortisol in men, but not in women. Administration of the panicogetic peptide cholecystokinin-tetrapeptide (CCK-4) induced copeptin release, which correlated with panic symptoms and secretion of ACTH and cortisol in non-obese men (mean age: 27.4 years) (Demiralay et al., 2017). In another study, Schinke et al. (2017) measured copeptin after dexamethasone administration and before CRH administration in the combined dexamethasone/CRH stimulation test. Copeptin levels were higher in obese subjects (mean age: 36.5 ± 10.0 years; body mass index (BMI): 41.5 ± 4.7 kg/m²) than normal-weight controls after dexamethasone administration. In the obese group, copeptin correlated positively with BMI, but not with age. Moreover, copeptin serum concentrations correlated positively with ACTH and cortisol curve indicators in obese men but not in non-obese controls and females, suggesting an interaction of the AVP system with HPA activation in obese men (Schinke et al., 2017).

Investigations of copeptin in stress-related disorders are scarce. Major depressive disorder (MDD) and adverse childhood experiences (ACE) such as abuse and neglect have complex and unfavourable long-term effects on both mental and physical health (Otte et al., 2016), which might be partially explained by HPA axis dysfunction (De Bellis & Zisk, 2014). Depressive symptoms were associated with copeptin plasma concentrations in young adults (mean age: 24.3 ± 2.97 years; female: 52.4%), with no differences between men and women (Thomsen et al., 2019). In another study, plasma copeptin concentrations were not significantly different between depressed subjects (mean age: 41.9 ± 11.2 years; female: 68.2%) and healthy controls (mean age: 40.6 ± 13.1 years; female: 64.9%), and no association was observed between copeptin and cortisol or ACTH (Krogh et al., 2013). Despite growing evidence for a role of copeptin in psychosocial stress, only one study has investigated whether copeptin is associated with the negative effects of ACE (Coelho et al., 2016), and showed that serum copeptin levels were higher in children with ACE than in children without ACE.

MDD and ACE are associated with sex-specific differences (McLean, Asnaani, Litz, & Hofmann, 2011). Women show higher prevalence rates for both, as well as higher symptom severity and comorbidity rates (Breslau, 2002). This contrasts with the lack of literature in this field and is underpinned by the vast heterogeneity and inconclusiveness of the available data. Therefore, the primary objective of our full-factorial exploratory study was to investigate the association between MDD with and without ACE and copeptin in physically healthy females. Moreover, as most findings were reported in children (e.g. Coelho et al., 2016) or young adults (e.g. Thomsen et al., 2019), we opted for adult women in order to extend the literature in this
population, since ACE has repeatedly been associated with mental impairments and disorders in later life (Gould et al., 2012; Kaczmarczyk, Wingenfeld, Kuehl, Otte, & Hinkelmann, 2018; Majer, Nater, Lin, Capuron, & Reeves, 2010; Pechtel & Pizzagalli, 2011). We hypothesized that plasma levels of copeptin would be positively correlated with MDD and ACE. Since a body of work shows immediate copeptin changes following a stressor task, a secondary aim was to analyse the effects of acute physiological stress on copeptin using the combined dexamethasone/CRH stimulation test, assuming that cortisol response markers would be positively associated with copeptin.

2. Methods and material

2.1. Participants

Our participants were part of the sample from a previously published study (Spitzer et al., 2017), and copeptin data were available for these participants. Ninety-four women were included: 23 with MDD and ACE (MDD +/ACE +), 24 with MDD without ACE (MDD +/ACE –), 22 with ACE but no current or lifetime MDD (MDD – /ACE +), and 25 healthy controls with no current or lifetime mental disorder and with no experiences of abuse (MDD – /ACE –).

2.2. Clinical assessment

All participants underwent a comprehensive clinical assessment including the Structured Clinical Interview for DSM-IV axis I and axis II conducted by a consultant psychiatrist or a licenced psychological psychotherapist.

Subjects with MDD met the clinical criteria for a DSM-IV diagnosis of current major depressive episode based on the SCID-I. Exclusion criteria included schizophrenia, schizoaffective and bipolar disorder, depressive episodes with psychotic features, posttraumatic stress disorder, anorexia, and substance dependence. Depression was measured using the Beck Depression Inventory (BDI-II) based on the self-report and clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS).

ACE was defined as repeated sexual or physical abuse at least once a month over at least one year before the age of 18 years (Heim et al., 2000b). The presence of ACE was determined in clinical interviews. Afterwards, severity was assessed psychometrically using the German version of the retrospective self-rated Childhood Trauma Questionnaire (CTQ) (Bernstein et al., 2003; Wingenfeld et al., 2010). Additionally, all subjects were interviewed using the Early Trauma Inventory (ETI) (Bremner, Vermetten, & Mazure, 2000; Wingenfeld et al., 2011).

Healthy controls also completed all clinical interviews and self-report questionnaires in the same manner as described above. No participant of either MDD – group had any current or lifetime mental disorder based on DSM-IV criteria. In order to be considered for either ACE – group (i.e. MDD +/ACE – and healthy controls), the participant had to be free of any adverse life event until the date of testing. This was ensured by extensive clinical interviews, checking for each of the main traumatic experiences (for example sexual harassment, physical abuse, accidents, war or natural disasters among many others). In case one participant reported a mild experience it was thoroughly investigated, whether this had any lasting effects or consequences for the subject. If this was the case, the participant was either excluded from participation, or, based on the criteria mentioned above, considered for one of the ACE + groups (resulting in two highly differing ACE +/ACE – groups).

Further exclusion criteria included neurological and severe metabolic, endocrine, or autoimmune diseases, current infections, pregnancy, and a BMI above 30 (since it is widely established that obesity is associated with a plethora of metabolic and endocrine changes).

2.3. Procedure

The study took place at the Department of Psychiatry and Psychotherapy (Campus Benjamin Franklin) of Charité – Universitätsmedizin Berlin. Participants were recruited via public postings and through affective disorder units. All subjects provided written informed consent and received monetary remuneration (€ 200 for the whole study). The study was approved by the local ethics committee. Blood samples were collected in the laboratory at 8 a.m. after an overnight fast (blood was taken with participants in the supine position and after rest for the same time before starting).

2.4. Combined dexamethasone/CRH stimulation test

In the combined dexamethasone/CRH stimulation test (performed on a separate day) all subjects received dexamethasone (oral; 1.5 mg) at 11:00 p.m. on the first study day and human CRH (intravenous; 100 μg) at 2:30 p.m. on the second study day. Salivary cortisol was collected using salivettes before (~60 min, ~30 min, immediately before CRH infusion) and after (+30 min, +60 min, +90 min, +120 min) CRH infusion. Cortisol response markers were baseline to peak (BtP; difference between the mean of the three baseline cortisol measures and the maximum value after CRH) and area under the curve (AUC; computed with respect to
ground) values (for further information see Spitzer et al., 2017).

### 2.5. Hormonal measures

**Copeptin**: Blood samples with EDTA added were placed on ice, immediately centrifuged at 4°C, and stored at −80°C until analysis. Copeptin concentrations were measured in the neurobiological laboratory of the Department of Psychiatry and Psychotherapy of the University Medical Centre Hamburg-Eppendorf using an immunoluminometric assay (B-R-A-H-M-S GmbH, Hennigsdorf, Berlin, Germany). Intra- and interassay coefficients of variation were below 4% and 7%, respectively. The detection limit was 1 pmol/l.

**Cortisol**: Salivary samples were stored at −80°C until analysis. Concentrations of free cortisol were measured in the neurobiological laboratory of the Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin. Intra- and interassay coefficients of variation were below 8% and 10%, respectively. All samples and standards were measured in duplicates.

### 2.6. Data analysis

Continuous variables were analysed with ANOVA and categorical variables with Chi² tests. Correlations were tested between copeptin and clinical parameters including age, BMI, clinician- and self-reported depression scales, clinician- and self-reported childhood trauma scales, and cortisol response markers of the combined dexamethasone/CRH stimulation test (BtP and AUC values). We performed a 2 (MDD +, MDD −) × 2 (ACE +, ACE −) ANCOVA with BMI as a covariate to analyse main effects and interaction effects on plasma copeptin concentrations.

### 3. Results

#### 3.1. Sample characteristics

Demographic and clinical data are shown in Table 1. The four groups did not differ significantly in age, BMI, smoking, years of education, and intake of oral contraceptives. Some women with MDD received antidepressants, but there was no significant difference in medication intake between the non-ACE and ACE group. Psychiatric comorbidities are presented in Table 1. No participants in the MDD −/ACE + group and no healthy controls had a mental disorder according to DSM-IV criteria. The MDD groups did not differ significantly in MADRS and BDI-II scores, but exhibited higher scores than both non-MDD groups did. CTQ and ETI sum scores were higher in both ACE groups than in the non-ACE groups.

#### Table 1. Sample characteristics of women with MDD with and without ACE and healthy women with and without ACE.

<table>
<thead>
<tr>
<th></th>
<th>MDD+/ACE + (N = 23)</th>
<th>MDD+/ACE − (N = 24)</th>
<th>MDD−/ACE + (N = 22)</th>
<th>MDD−/ACE − (N = 25)</th>
<th>statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Years</td>
<td>32.74 (10.6)</td>
<td>35.79 (10.4)</td>
<td>35.68 (11.5)</td>
<td>32.00 (11.2)</td>
</tr>
<tr>
<td>Years of education</td>
<td></td>
<td>11.09 (1.5)</td>
<td>11.13 (1.4)</td>
<td>11.50 (1.3)</td>
<td>11.70 (1.3)</td>
</tr>
<tr>
<td>Body mass index</td>
<td>kg/m²</td>
<td>22.45 (3.3)</td>
<td>22.62 (4.2)</td>
<td>24.07 (3.3)</td>
<td>21.51 (3.2)</td>
</tr>
<tr>
<td>Smoking</td>
<td>Yes/No</td>
<td>11/12</td>
<td>8/16</td>
<td>6/16</td>
<td>6/19</td>
</tr>
<tr>
<td>Intake of oral contraceptives</td>
<td>Yes/No</td>
<td>7/16</td>
<td>8/16</td>
<td>5/17</td>
<td>7/18</td>
</tr>
<tr>
<td>Psychotropic medication</td>
<td>Yes/No</td>
<td>6/17ª</td>
<td>6/17ª</td>
<td>0/22</td>
<td>0/25</td>
</tr>
<tr>
<td>SNRI</td>
<td></td>
<td>2</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>SSRI</td>
<td></td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>NDRI</td>
<td></td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td></td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td></td>
<td>2</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Agomelatine</td>
<td></td>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Major depressive episode</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MADRS</td>
<td>Sum score</td>
<td>32.91 (6.7)</td>
<td>29.67 (6.6)</td>
<td>2.77 (2.3)</td>
<td>0.52 (0.9)</td>
</tr>
<tr>
<td>BDI-II</td>
<td>Sum score</td>
<td>26.39 (10.6)</td>
<td>26.92 (8.0)</td>
<td>9.42 (7.1)</td>
<td>2.76 (3.1)</td>
</tr>
<tr>
<td>Anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STAI trait</td>
<td>Sum score</td>
<td>47.52 (4.7)</td>
<td>48.93 (6.1)</td>
<td>42.05 (5.9)</td>
<td>41.60 (2.4)</td>
</tr>
<tr>
<td>Adverse childhood experiences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETI</td>
<td>Sum score</td>
<td>578.61 (352.77)</td>
<td>388.20 (377.30)</td>
<td>710.05 (334.89)</td>
<td>23.80 (43.49)</td>
</tr>
<tr>
<td>CTQ</td>
<td>Sum score</td>
<td>62.63 (16.3)</td>
<td>64.12 (14.0)</td>
<td>65.86 (19.2)</td>
<td>28.33 (3.5)</td>
</tr>
<tr>
<td>Copeptin pmol/l (SEM)</td>
<td>4.70 (0.64)</td>
<td>4.58 (1.01)</td>
<td>4.70 (0.52)</td>
<td>4.36 (0.56)</td>
<td>p = .982</td>
</tr>
</tbody>
</table>

### Abbreviations

MDD+/ACE + = MDD subjects with ACE, MDD+/ACE − = MDD subjects without ACE, MDD−/ACE + = subjects with ACE but no MDD, MDD−/ACE − = healthy controls, BMI = body mass index, OC = oral contraceptives, SNRI = serotonin and noradrenaline reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor, NDRRI = dopamine and noradrenaline reuptake inhibitor, BDI-II = Beck Depression Inventory, MADRS = Montgomery–Åsberg Depression Rating Scale, STAI = State-Trait Anxiety Inventory, ETI = Early Trauma Inventory, CTQ = Childhood Trauma Questionnaire, SEM = standard error of the mean.

Anticonvulsants: pregabalin
*ª subjects had 2 drugs.
† subjects had 2 drugs.
MDD+/ACE + = 9 subjects reported psychiatric comorbidities (6 subjects with persistent depressive disorder, 2 subjects with panic disorder, 1 subject with social anxiety disorder)
MDD+/ACE − = 8 subjects reported psychiatric comorbidities (2 subjects with agoraphobia, 1 subject with borderline personality disorder, 2 subjects with persistent depressive disorder, 3 subjects with social anxiety disorder)
3.2. Correlations between copeptin and demographic variables

BMI correlated negatively with plasma copeptin 
\((r = -0.21; p < 0.045)\) (Figure 1(a)), so we included BMI in all further analyses. Other demographic variables (including age) did not significantly correlate with copeptin levels.

No psychopathology scores correlated significantly with copeptin (MADRS: \(r = -0.048; p = 0.653\); BDI-II: \(r = -0.047; p = 0.663\); STAI trait: \(r = -0.040; p = 0.707\); ETI: \(r = -0.039; p = 0.711\); CTQ: \(r = -0.124; p = 0.243\)).

3.3. Effects on copeptin

2 × 2 ANCOVA with BMI as a covariate did not reveal a significant main effect of MDD (\(F(1,85) = 0.017; p = 0.895\)) or ACE (\(F(1,85) = 0.490; p = 0.486\)) on copeptin plasma levels (Figure 1(b)). The interaction between MDD and ACE was not significant (\(F(1,85) = 0.292; p = 0.590\)). Exploratory analyses for the overall sample revealed a significant negative correlation between copeptin and the cortisol response markers of the combined dexamethasone/CRH stimulation test (BiP: \(r = -0.231; p = 0.031\); AUC: \(r = -0.225; p = 0.036\)).

Figure 1. (a) Negative correlation between body mass index (BMI) and plasma copeptin levels in the overall sample. (b) Mean plasma copeptin levels. A 2 × 2 ANCOVA with BMI as covariate revealed no main effect of MDD or ACE, nor a significant MDD by ACE interaction effect. Depiction of mean value and standard error of the mean.
4. Discussion

In this study, we did not detect any significant association between copeptin and MDD or a history of ACE in an adult, all-female sample.

Our finding that copeptin levels are not altered in individuals with MDD agree with those of Krogh et al. (2013), who found no difference in copeptin levels between depressed patients and healthy subjects. We expand these findings by including ACE in the present study. Our finding that copeptin levels are not altered in individuals with ACE is in contrast to a cross-sectional investigation which showed higher serum copeptin levels in children with ACE compared with controls, independent of age, sex, and symptom severity (Coelho et al., 2016). The design of this previous study was very similar to ours – the inclusion criteria were similar (i.e., good physical health, history of either moderate to severe ACE or no ACE) and the sample sizes of the ACE + and ACE – groups were similar too. The similar design suggests that this discrepancy may be explained by an influence of age; this should be investigated in future studies. Another possible explanation could be sex-related differences, as Coelho et al. (2016) included males and females in their study (ACE +: 47.8% female; ACE –: 52.2% female) whereas we only included females.

Our all-female sample was different to the mixed samples investigated by Thomsen et al. (2019) and Coelho et al. (2016). Not only basal copeptin concentrations (Burckhardt et al., 2014) but also the effects of stress on copeptin levels (Spanakis et al., 2016) seem to be sex-specific and thus are different in males and females. Copeptin levels were significantly lower in women than men before CCK-4 was applied to induce panic-like symptoms, while men showed a significantly higher increase of copeptin levels after CCK-4 was administered (Kellner et al., 2019). We decided to study an all-female population to eliminate any sex-specific effects and determine whether copeptin levels are altered in female individuals with MDD and ACE.

Copeptin levels correlated negatively with BMI in our study; as BMI increased, copeptin plasma concentrations decreased. In another study, a positive correlation between copeptin levels and BMI was observed in obese males, but not in women and non-obese controls (Schinke et al., 2017).

Exploratory analyses revealed a negative correlation between copeptin levels and cortisol increase (measured by BTP and AUC values in the combined dexamethasone/CRH stimulation test). Schinke et al. (2017) found that copeptin levels (after dexamethasone) correlated positively with ACTH and cortisol release in obese males but not in females.

There are strengths and limitations to our study. We studied a homogenous sample of female subjects. As described above, all diagnoses were based on extensive clinical interviews. Our full-factorial study design allowed us to infer conclusions on the differential effects of MDD and ACE. However, we cannot generalize our findings to men. The literature on the association between psychosocial stress and stress-related disorders with copeptin generally shows immediate effects (i.e., following a stressor task) in males. We decided to investigate adult females due to the previously mentioned sex-specific differences in MDD and ACE. Therefore, future studies should further investigate whether affected persons of different sex and age show the same pattern of effects on copeptin. Another limitation is the retrospective assessment of ACE and the cross-sectional design of our study. We measured copeptin on only one occasion. We were thus unable to deduce whether copeptin might be altered in relation to an acute traumatic experience, or if copeptin changes precipitate traumatic events, or if the level of copeptin and the development of psychopathology are in any way related. We assume that the lack of consistency in the field at this point might also be due to the heterogeneity of the methods applied (pharmacologically induced stress (combined dexamethasone/CRH stimulation test), social stressors in laboratory settings (TSST), acute real-life stressful situations (exams, hospital admissions) as well as chronic real-life stressors (childhood maltreatment)) and the varying definitions and measures of MDD and ACE. We also did not measure osmolality; therefore, we could not control for water balance when interpreting copeptin concentrations. Additionally, establishment of normal ranges and as a clinical parameter or biomarker is yet to be implemented.

Research into the association of copeptin with psychosocial stress and mental disorders has just started. It is not yet known whether increased copeptin levels are short-term increases in response to acute stress (state marker) or rather reflect long-term changes (trait marker). Further studies are needed to clarify these issues and to characterize the influence of age and sex on copeptin secretion.

Acknowledgments

We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité – Universitätsmedizin Berlin.

Disclosure statement

CO has received honoraria for lectures and/or scientific advice from Allergan, Ferring, Fortbildungscolleg, Limes Klinikgruppe, Lundbeck, MedOnline, Medical Tribune, Neuraxpharm, SAGE Therapeutics, and Stillachhaus. All other authors reported no potential conflicts of interest.
The study was supported by German Research Foundation (DFG) grants [WI 3396/6-1 and SP 579/3-1] awarded to KW, CS, and CO. MK participated in the BIH – Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health.

Michael Kaczmarczyk  http://orcid.org/0000-0003-2366-5972
Carsten Spitzer  http://orcid.org/0000-0002-2711-285X
Katja Wingenfeld  http://orcid.org/0000-0001-7457-0370

ORCID

The data availability statement

The data that support the findings of this study are available from the authors upon reasonable request (please contact Katja Wingenfeld: katja.wingenfeld@charite.de). The data are not publicly available due to legal and ethical restrictions.

References


Bremner, J. D., Vermetten, E., & Mazure, C. M. (2000). Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: The Early Trauma Inventory. Depression and Anxiety, 12(1), 1–12.


